Gilead Sciences COO Kevin Young to Retire
On Thursday, September 28, after Gilead Sciences’ (NASDAQ:$GILD) COO Kevin Young announced his plans to retire early next year, the biotech company’s shares dropped 4.7% in extremely heavy trade. Alethia Young, Credit Suisse analyst, says ... [Read]
Shares of PTC Therapeutics Dropped Today, Here’s Why
As of 11:53 a.m. EDT on Tuesday, September 26, shares of PTC Therapeutics (NASDAQ:$PTCT) dropped 17.3%. What Happened? After briefing documents were released to the public, investors were left feeling hopeless that an upcoming independent ... [Read]
Versartis Shares Plunged a Whopping 82% Today
Versartis Inc. (NASDAQ:$VSAR) shares plunged a whopping 82% late Thursday. Why? It all started after the California-based biopharmaceutical company announced that its drug Somavaratan failed to meet its endpoint in a phase 3 trial. The ... [Read]
Intercept Pharmaceuticals Plunged Today, Here’s Why
On Thursday, September 21, as of 3:26 p.m. EDT, Intercept Pharmaceuticals (NASDAQ:$ICPT) plunged 21%. What happened? Well, the fall began after the FDA released a safety announcement warning the public that when Intercept’s liver disease ... [Read]
Nabriva Therapeutics Stock Increased Today, Here’s Why
If you’re looking to get into biotech investing, you might want to think about adding Nabriva Therapeutics (NASDAQ:$NBRV) to your investment portfolio. For the second day in a row, the company is witnessing double-digit gains. ... [Read]
The Recipe Behind Abeona Therapeutics’ 6 Months Dominance
As of 2:50 EDT, Abeona Therapeutics (NASDAQ:$ABEO) have surged a whopping 18%. This came after an analyst from RBC Capital granted the biotech company an outperform rating and assigned a $23 price target, more than ... [Read]
Intercept Pharmaceuticals Stock Is Falling Today, Here’s Why
As of 10:30 a.m. EDT, shares of Intercept Pharmaceuticals (NASDAQ:$ICPT) declined by 17%. Why? Many speculate the fall was caused by a letter that was sent by Intercept’s Chief Medical Officer to the medical community ... [Read]
Idera Pharmaceuticals Climbs 16.9%, Phase 3 Study Proceeds
A clinical-stage biotech company advancing novel therapies for skin-related diseases, Idera Pharmaceuticals Inc. (NASDAQ:$IDRA) saw its shares surge today. This came after the company presented trial results at the annual European Society for Medical Oncology ... [Read]
Wall Street’s Bull of The Day: Kura Oncology
Kura Oncology Inc. (NASDAQ:$KURA)’s shares are up 90%, rightfully deserving of Wall Street’s bull of the day title. What’s their secret? The biotech company announced positive top-line results from a phase II trial for its ... [Read]
Here’s Why Immune Design is Down 6.8% Since the Last Earnings Report
Plummeting 6.8%, way outperforming the market, Immune Design Corp. (NASDAQ:$IMDZ)’s shares are suffering a serious outlook. Let’s take a look back on Immune Design’s last earnings report. Narrower-than-expected Loss in Q2 The company incurred 2Q17 ... [Read]